Free Trial

ACADIA Pharmaceuticals (ACAD) Competitors

ACADIA Pharmaceuticals logo
$20.95 -0.29 (-1.37%)
Closing price 07/3/2025 03:39 PM Eastern
Extended Trading
$20.95 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACAD vs. ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, BPMC, BBIO, and VRNA

Should you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry.

ACADIA Pharmaceuticals vs. Its Competitors

Intra-Cellular Therapies (NASDAQ:ITCI) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Intra-Cellular Therapies has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

In the previous week, ACADIA Pharmaceuticals had 10 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 10 mentions for ACADIA Pharmaceuticals and 0 mentions for Intra-Cellular Therapies. ACADIA Pharmaceuticals' average media sentiment score of 0.64 beat Intra-Cellular Therapies' score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Intra-Cellular Therapies Neutral
ACADIA Pharmaceuticals Positive

ACADIA Pharmaceuticals has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64
ACADIA Pharmaceuticals$957.80M3.66$226.45M$1.3715.29

ACADIA Pharmaceuticals has a net margin of 22.97% compared to Intra-Cellular Therapies' net margin of -14.07%. ACADIA Pharmaceuticals' return on equity of 17.46% beat Intra-Cellular Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Intra-Cellular Therapies-14.07% -9.93% -8.38%
ACADIA Pharmaceuticals 22.97%17.46%10.75%

Intra-Cellular Therapies presently has a consensus target price of $109.70, indicating a potential downside of 16.81%. ACADIA Pharmaceuticals has a consensus target price of $27.88, indicating a potential upside of 33.05%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Intra-Cellular Therapies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intra-Cellular Therapies
0 Sell rating(s)
10 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
ACADIA Pharmaceuticals
0 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.71

92.3% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by insiders. Comparatively, 26.5% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Intra-Cellular Therapies on 15 of the 17 factors compared between the two stocks.

Get ACADIA Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACAD vs. The Competition

MetricACADIA PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.51B$2.89B$5.49B$9.01B
Dividend YieldN/A2.43%5.38%4.09%
P/E Ratio15.2921.5627.4220.26
Price / Sales3.66245.52407.97121.21
Price / Cash30.1341.9536.6357.47
Price / Book4.767.518.085.67
Net Income$226.45M-$55.05M$3.16B$248.47M
7 Day Performance-5.29%4.59%2.81%3.29%
1 Month Performance-3.77%4.86%3.68%5.19%
1 Year Performance34.38%5.82%35.29%21.35%

ACADIA Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACAD
ACADIA Pharmaceuticals
4.7016 of 5 stars
$20.95
-1.4%
$27.88
+33.1%
+34.4%$3.51B$957.80M15.29510
ITCI
Intra-Cellular Therapies
0.9951 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
3.597 of 5 stars
$20.68
-2.3%
$39.17
+89.4%
-18.8%$13.26B$3.12B11.752,682High Trading Volume
RDY
Dr. Reddy's Laboratories
2.8739 of 5 stars
$15.31
+0.5%
$16.95
+10.7%
-0.9%$12.78B$3.81B23.2027,811
ASND
Ascendis Pharma A/S
3.6797 of 5 stars
$175.78
-0.6%
$220.67
+25.5%
+29.7%$10.75B$393.54M-27.991,017Analyst Forecast
VTRS
Viatris
3.2803 of 5 stars
$8.85
-0.2%
$10.40
+17.5%
-10.9%$10.39B$14.74B-2.7932,000
QGEN
Qiagen
4.0679 of 5 stars
$46.72
-0.1%
$47.74
+2.2%
+22.5%$10.39B$2.00B117.145,765Dividend Announcement
MRNA
Moderna
4.391 of 5 stars
$25.67
-0.9%
$46.61
+81.6%
-73.7%$9.93B$3.14B-2.945,800Options Volume
BPMC
Blueprint Medicines
1.7469 of 5 stars
$128.40
+0.2%
$128.06
-0.3%
+17.6%$8.29B$508.82M-51.98640High Trading Volume
BBIO
BridgeBio Pharma
4.7106 of 5 stars
$42.17
+1.1%
$56.67
+34.4%
+74.8%$8.01B$127.42M-11.95400Insider Trade
Analyst Revision
VRNA
Verona Pharma PLC American Depositary Share
2.6669 of 5 stars
$97.05
+2.9%
$101.10
+4.2%
+480.4%$7.87B$118.54M-48.5330Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ACAD) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners